Bristol Myers licenses immunotherapy from Dragonfly

By The Science Advisory Board staff writers

August 10, 2020 -- Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio.

The deal will allow Dragonfly to further develop new natural killer cell-based treatment options for patients with cancer, autoimmune disease, and neurological conditions, it said. This is the fourth licensing agreement between the two firms since 2017.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.